Treatment and prevention of multidrug-resistant tuberculosis

被引:81
|
作者
Bastian, I [1 ]
Colebunders, R [1 ]
机构
[1] Inst Trop Med, B-2000 Antwerp, Belgium
关键词
D O I
10.2165/00003495-199958040-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multidrug-resistant tuberculosis (MDRTB), which is defined as combined resistance to isoniazid and rifampicin, is a 'man-made' disease that is caused by improper treatment, inadequate drug supplies or poor patient supervision. Patients with MDRTB face chronic disability and death, and represent an infectious hazard for the community. Cure rates of 96% have been achieved but require prompt recognition of the disease, rapid accurate susceptibility results, and early administration of an individualised re-treatment regimen. Such regimens are usually based on a quinolone and an injectable agent (i.e. an aminoglycoside or capreomycin) supplemented by other 'second-line' drugs. This therapy is prolonged (e.g. 24 months), expensive, and has multiple adverse effects. Prevention of MDRTB is therefore of paramount importance. The World Health Organization (WHO) has recommended a multifaceted programme, known by the acronym DOTS (directly observed therapy, short-course), that promotes effective treatment of drug-susceptible TB as the prime method of limiting drug resistance. DOTS was part of a successful MDRTB control programme in New York City, which also included treatment of prevalent MDRTB cases, streamlined laboratory testing, effective infection control procedures and wider application of screening and preventive therapy (although the optimal chemotherapy for MDRTB infection remains undefined). Industrialised countries have the resources to treat patients with MDRTB and to mount these extensive control programmes. Unfortunately, MDRTB is also prevalent in Asia, South America and the former Soviet Union. First world countries have a vested interest, as well as a moral responsibility, to assist in controlling MDRTB in these 'hot spots'.
引用
收藏
页码:633 / 661
页数:29
相关论文
共 50 条
  • [1] Treatment and Prevention of Multidrug-Resistant Tuberculosis
    Ivan Bastian
    Robert Colebunders
    [J]. Drugs, 1999, 58 : 633 - 661
  • [2] TREATMENT AND PREVENTION OF MULTIDRUG-RESISTANT TUBERCULOSIS
    COHN, DL
    ISEMAN, MD
    [J]. RESEARCH IN MICROBIOLOGY, 1993, 144 (02) : 150 - 153
  • [3] Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis
    Sterling, T. R.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (12) : S42 - S47
  • [4] Treatment of multidrug-resistant tuberculosis
    Colebunders, R
    Apers, L
    Shamputa, IC
    [J]. LANCET, 2004, 363 (9416): : 1240 - 1240
  • [5] TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS
    COHN, DL
    [J]. JOURNAL OF HOSPITAL INFECTION, 1995, 30 : 322 - 328
  • [6] Treatment Outcomes in Multidrug-Resistant Tuberculosis
    Guenther, Gunar
    Lange, Christoph
    Alexandru, Sofia
    Altet, Neus
    Avsar, Korkut
    Bang, Didi
    Barbuta, Raisa
    Bothamley, Graham
    Ciobanu, Ana
    Crudu, Valeriu
    Danilovits, Manfred
    Dedicoat, Martin
    Duarte, Raquel
    Gualano, Gina
    Kunst, Heinke
    de Lange, Wiel
    Leimane, Vaira
    Magis-Escurra, Cecile
    McLaughlin, Anne-Marie
    Muylle, Inge
    Polcova, Veronika
    Popa, Christina
    Rumetshofer, Rudolf
    Skrahina, Alena
    Solodovnikova, Varvara
    Spinu, Victor
    Tiberi, Simon
    Viiklepp, Piret
    van Leth, Frank
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (11): : 1103 - +
  • [7] Surgery in the treatment of multidrug-resistant tuberculosis
    Pomerantz, M
    Brown, JM
    [J]. CLINICS IN CHEST MEDICINE, 1997, 18 (01) : 123 - &
  • [8] Diagnosis and treatment of multidrug-resistant tuberculosis
    Kang, Young Ae
    [J]. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2014, 57 (01): : 27 - 33
  • [9] Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
    Schecter, G. F.
    Scott, C.
    True, L.
    Raftery, A.
    Flood, J.
    Mase, S.
    [J]. CLINICAL INFECTIOUS DISEASES, 2010, 50 (01) : 49 - 55
  • [10] Delamanid in the treatment of multidrug-resistant tuberculosis
    Gupta, R.
    Wells, C. D.
    Hittel, N.
    Hafkin, J.
    Geiter, L. J.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (12) : S33 - S37